HIGH INTENSITY LASER THERAPY ON WOUND CARE
High-Intensity Laser Therapy (HILT) is promising as an adjunct for chronic wound care, but it is not yet supported by enough high-quality evidence to be considered a replacement for standard wound management.
What’s new
1. HILT has encouraging clinical evidence in chronic refractory wounds.
A randomized controlled trial of 59 patients found that adding HILT to conventional wound care produced significantly greater improvements in wound-assessment and PUSH scores after 3 weeks than conventional care alone.
2. But the evidence base is still relatively small.
A 2024 narrative review specifically examining HILT for wound healing concluded that the results are promising, but there are insufficient high-quality data to establish the optimal laser parameters or definitively prove clinical efficacy.
3. The bigger field of photobiomodulation is moving toward standardized dosing.
A 2026 systematic review of randomized trials of LED photobiomodulation for chronic lower-limb wounds found possible improvements in wound area, wound-bed quality and microcirculation—particularly in diabetic foot ulcers—but rated the overall certainty of evidence very low because of small studies, heterogeneity and inconsistent protocols. Interestingly, a very high energy density did not produce benefit, reinforcing that dose matters.
Where HILT may fit in advanced wound care
The most interesting potential applications are:
- Diabetic foot ulcers
- Chronic refractory wounds
- Venous/vascular ulcers
- Pressure injuries
- Postsurgical wounds with delayed healing
- Possibly complex wounds after adequate debridement and infection/ischemia management
The proposed effects include modulation of inflammation, stimulation of cellular activity, angiogenesis/microcirculation, collagen remodeling and acceleration of tissue repair.
The important distinction
There is a tendency to lump all “laser therapy” together, but HILT, low-level laser therapy (LLLT), LED photobiomodulation, fractional CO₂ laser and ablative laser debridement are not the same treatment.
For example, recent literature on fractional lasers suggests potential benefits through controlled tissue remodeling, debridement, bacterial-load reduction and stimulation of repair pathways—but protocols remain highly variable.
So when evaluating a HILT wound-care program, I would pay particular attention to:
wavelength → power → energy density (J/cm²) → pulse characteristics → treatment distance → frequency → wound type → wound depth → treatment endpoint.
My 2026 assessment
I’d currently place HILT at:
🟢 Biological plausibility: Strong
🟢 Early clinical signal: Promising
🟡 Evidence quality: Moderate-to-low
🟡 Protocol standardization: Poor
🔴 Evidence for replacing standard wound care: Insufficient
The strongest position today is therefore:
HILT should be considered an adjunctive technology within a comprehensive advanced wound-care program—not a stand-alone wound-healing treatment.
And this is actually where I think the field gets particularly interesting: combining HILT with debridement, infection control, off-loading/compression, vascular optimization, advanced dressings and biologic therapies may ultimately prove more valuable than HILT alone.
P.S.
HILT is available at our Advanced Wound Care Center for a limited time only. Come soon to avail of this treatment.